

Citation for published version:
Aaron, RV, Fisher, EA, de la Vega, R, Lumley, MA & Palermo, TM 2019, 'Alexithymia in individuals with chronic pain and its relation to pain intensity, physical interference, depression, and anxiety: a systematic review and meta-analysis', Pain, vol. 160, no. 5, pp. 994-1006. https://doi.org/10.1097/j.pain.0000000000001487

10.1097/j.pain.0000000000001487

Publication date: 2019

Document Version Peer reviewed version

Link to publication

This is the author accepted manuscript of a paper published in final form in Aaron, RV, Fisher, EA, de la Vega, R, Lumley, MA & Palermo, TM 2019, 'Alexithymia in individuals with chronic pain and its relation to pain intensity, physical interference, depression, and anxiety: a systematic review and meta-analysis', Pain, vol. 160, no. 5, pp. 994-1006 and available online via: https://doi.org/10.1097/j.pain.000000000001487

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 05 Jun 2020

Alexithymia in Individuals with Chronic Pain and its Relation to Pain Intensity, Physical Interference, Depression and Anxiety: A Systematic Review and Meta-Analysis

Rachel V. Aaron^{1,2},*, Emma Fisher³, Rocio de la Vega^{1,2}, Mark A. Lumley⁴, Tonya M. Palermo^{1,2}

¹University of Washington, Seattle, USA;

²Seattle Children's Research Institute, Seattle, USA;

³University of Bath, Bath, UK;

⁴Wayne State University, Detroit, MI, USA

*Corresponding author. Current address: Johns Hopkins Medicine, 1800 Orleans St., Baltimore, MD 21287; 410-502-2441; raaron4@jhmi.edu

Abstract

Numerous studies have examined how alexithymia (difficulty identifying and describing one's emotions and a preference for externally-oriented thinking) relates to chronic pain and associated disability. We conducted a systematic review and meta-analysis to summarize individual studies that either assessed alexithymia in individuals with chronic pain versus controls or related alexithymia to pain intensity, physical interference, depression and anxiety. We searched

MEDLINE, Embase and PsycINFO from inception through June 2017; 77 studies met criteria (valid assessment of alexithymia in adults or children with any chronic pain condition) and were included in analyses (n = 8019 individuals with chronic pain). Primary analyses indicated that chronic pain samples had significantly higher mean alexithymia scores compared to non-clinical (d = 0.81) and clinical non-pain (d = 0.55) controls. In chronic pain samples, alexithymia was significantly positively associated with pain intensity (d = 0.20), physical interference (d = 0.17), depression (d = 0.46), and anxiety (d = 0.43). Secondary meta-analyses of 14 studies that conducted partial correlations that controlled for negative affect-related measures revealed that alexithymia was no longer significantly related to pain intensity or interference. Meta-analysis findings demonstrated that alexithymia is elevated in individuals with chronic pain and related to greater pain intensity and physical interference, although the latter relationships may be accounted for by negative affect. Critical future work is needed that examines alexithymia assessed using non-self-report measures, develops a person-centered perspective on this construct, and identifies how alexithymia is relevant to the assessment and treatment of individuals with chronic pain.

Keywords: chronic pain, alexithymia, pain intensity, physical interference

Introduction

Chronic pain is common, occurring in around 11% – 31% of adults [52; 89] and children [48; 57]. Chronic pain impacts physical, social, and emotional functioning [14; 95] and can be severely disabling [48; 89]. Chronic pain is also associated with heightened symptoms of depression and anxiety [2; 91; 104]. Given the high costs and societal burden of chronic pain [32; 39] identifying biopsychosocial treatment targets to improve functioning in this population is critical.

Individual differences in emotional awareness may relate to the experience of chronic pain, and various constructs within this domain have been studied and debated. One specific concept, labeled with the term alexithymia, has received considerable theoretical and empirical attention over the past several decades [120]. Alexithymia refers to the inability to label and describe one's emotions and a preference for externally-oriented thinking [112]. Alexithymia has been assessed primarily with self-report measures, the most common of which is the Toronto Alexithymia Scale-20 (TAS-20; [6]). Alexithymia has been found to be elevated in adults and youth with chronic pain compared to healthy samples [23; 33], and may be associated with greater pain intensity and disability [3; 74]. In addition, alexithymia is associated with greater depressive and anxiety symptoms in various populations [65; 66] including individuals with chronic pain [25]. This may be because alexithymia relates to reduced ability to successfully regulate, or reduce, negative emotion [117]. Although a number of factors – such as selfefficacy, stressor intensity, contextual cues, and cultural norms – influence an individual's choice of emotion regulation strategy, increased awareness of one's emotional states is thought to be key to taking active steps towards adaptive emotion regulation [41; 56]. In his extended process theory of emotion regulation, Gross [41] explains that emotion identification enables an

individual to take adaptive steps to regulate their emotions, and is thus an essential first step in the emotion regulation process. Lieberman and colleagues [67; 68] show that the simple act of applying a verbal label to one's emotional state results in reductions in negative affect both subjectively and neurologically, further demonstrating the emotion regulating properties of emotional awareness.

Although the majority of research examining the relationship between alexithymia and chronic pain has relied on cross-sectional methods, some prospective studies show alexithymia may constitute a risk factor for pain outcomes [10; 102]. Recent research highlights the malleability of alexithymia with psychological interventions [11; 15; 81], which increases the relevance of alexithymia to chronic pain clinical practice. For example, in a recent single-arm trial, adults with chronic musculoskeletal pain undergoing group intervention targeting emotional awareness and expression demonstrated improvements in alexithymia, which were associated with reductions in psychological distress as well as improvements in pain intensity and interference [13]. A better understanding of the relationship between alexithymia and chronic pain has potential to clarify aspects of emotion awareness that relate to chronic pain and lead to more specific psychological prevention or intervention programs to improve emotional functioning in individuals with chronic pain.

A great deal of research has examined alexithymia in individuals with chronic pain; however, no systematic reviews or meta-analyses of this literature have been conducted to summarize individual studies and provide estimates of the magnitude of the relationships between alexithymia and relevant pain variables. We conducted a systematic review of alexithymia in people with chronic pain and its relation to pain intensity, physical interference, anxiety, and depression. Specifically, we had three primary aims: (1) to determine levels of

alexithymia in adults and youth with chronic pain; (2) to estimate the magnitude of the difference in alexithymia levels between samples with chronic pain and various comparison samples; and (3) to estimate the associations between alexithymia and pain intensity, physical function, and symptoms of depression and anxiety in people with chronic pain. There is ongoing debate in this field as to whether observed associations between measures of alexithymia, pain intensity and functional impairment are confounded by depression or psychological distress [45; 77]. Thus, a secondary aim was to identify and summarize studies that covaried measures of negative affect when testing the relationship between alexithymia and pain intensity and interference. In conducting the present systematic review and meta-analysis, we hope to make the available evidence more accessible, to facilitate a critical examination of the application of this construct, and to generate broad conclusions that help pave the path for next steps in the area of emotions and pain.

Methods

The systematic review and meta-analysis protocol for the current study was registered on September 25th, 2017 and can be found through PROSPERO (ID: CRD42017077551).

Search Methods

We conducted systematic searches in Medline, PsycINFO, and EMBASE, from the inception of each database through June 2017. We included general search terms of "pain," "alexithymia," and related search terms to capture all studies conducted in this area. See Appendix for the specific search criteria. Two authors (RA and EF) independently sorted through abstracts to determine possible relevance (available as supplemental digital content at http://links.lww.com/PAIN/A734). The two resulting abstract lists were then reviewed together, and inconsistencies were resolved. Where disagreements emerged, a third author (TP) was

consulted until 100% agreement was achieved. Next, articles identified as possibly relevant were reviewed in full to determine their eligibility against inclusion/exclusion criteria. Once a final set of studies was generated from our search, we reviewed their reference lists to ensure other relevant articles had not been overlooked. Studies identified in this manner were then reviewed and assessed for eligibility. In addition, as described below, we contacted authors of articles that were missing key data or analyses to request those data.

Inclusion Criteria

Inclusion criteria for individual studies were the following: (1) included youth (<18 years) or adults (≥18 years) with chronic pain conditions including, but not limited to, headache, abdominal pain, musculoskeletal pain, and autoimmune disease-related pain; (2) assessed alexithymia using an established, psychometrically-sound measure; and (3) published in English in a peer-reviewed journal.

Exclusion Criteria

We excluded studies that: (1) included chronic pain participants with primary psychiatric diagnoses (e.g., substance abuse); (2) combined individuals with acute and chronic pain without reporting data separately for these groups; (3) screened and recruited based on "high" or "low" alexithymia; and (4) had less than 20 participants.

Data extraction

Data were extracted by RA and RV. We extracted only the baseline data from longitudinal studies. When data from the same study were published in different articles, we extracted data from the earliest published article that met our inclusion criteria, unless a subsequently published article reported a larger sample size. Some studies provided data on distinct pain samples (e.g., people with fibromyalgia vs headache). Some studies also provided

data on non-clinical comparison samples and/or non-pain clinical samples (e.g., diabetes). These data were extracted separately.

Study Characteristics. We extracted study characteristics including sample size, chronic pain characteristics (condition, location, duration), and demographic information (age, sex, country of study) from included studies. When studies included a comparison sample, we extracted the sample size and type of comparison.

Alexithymia. Measures of alexithymia typically yield a continuous alexithymia score and a clinical cutoff score. The most commonly-used measure, the Toronto Alexithymia Scale-20 (TAS-20; [6]), which was adapted from the original 26-item TAS [5]. The TAS-20 yields a continuous score ranging from 20-100, with higher scores indicating greater alexithymia and a clinical cutoff score of \geq 61, indicating elevated alexithymia [108]. The TAS-20 has three subscales: difficulty identifying feelings (DIF), difficulty describing feelings (DDF), and externally-oriented thinking (EOT). The Alexithymia Questionnaire for Children (AQC) [105] is parallel to the TAS-20 but is linguistically adapted for children. We extracted mean alexithymia total and subscale scores, and percentage of people above clinical cut-off scores in both chronic pain and comparison samples. We also recorded information on how alexithymia was assessed (i.e., assessment tool, scoring parameters).

Correlation Analysis. We extracted correlation coefficients describing the relationship between alexithymia and pain intensity, physical interference, anxiety, and depression. Some studies have examined partial correlations between alexithymia and pain intensity and physical interference while controlling for an index of depression or psychological distress. In the present review, we identified studies that conducted such partial correlations and extracted the resulting correlation coefficients for use in a secondary meta-analysis of partial correlations. A number of

studies reported correlations selectively, based on significance. Where we were unable to achieve representative analyses, we applied a rule established *a priori* to exclude selectively reported findings to avoid biasing results towards statistically significant findings.

Study Quality. For the purpose of better characterizing studies included in the metaanalysis, we extracted information related to study quality. We adapted the National Institutes of
Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [90],
excluding items that were irrelevant or inconsistent with our study inclusion/exclusion criteria.

Of the remaining items, some were adapted or reworded to more directly align with our criteria.

Given the numerous international studies in this field, we evaluated whether authors included an
alexithymia measure that had been validated in their country's language. We assigned studies
one point per each criterion met, which were summed for a total quality score of 0 - 8 (0
indicating lowest quality and 8 highest quality).

Missing Data. Of studies that met our inclusion criteria, many were missing some or all data points relevant to our meta-analyses. In many cases, it was clear from the authors' methods section that relevant variables had been measured. Specifically, we requested: (1) means and SDs of alexithymia total and subscale scores; (2) correlations between alexithymia and key variables (pain intensity, physical interference, depression, and anxiety); and (3) partial correlations of alexithymia with pain intensity and physical interference, controlling for negative affect (e.g., explicit measures of negative, depression, or anxiety). We provided one follow-up email for those authors who did not initially respond.

Data Analysis

For Aim 1, we summarized alexithymia (total and subscales) scores and percentage of people exceeding clinical cut-off scores separately for adults and youth with chronic pain. All pooled means were calculated using the formula indicated in Higgins and Green [44] (p. 177).

For Aim 2, we meta-analyzed the effect sizes of group differences in alexithymia scores between chronic pain and comparison groups with random effects models, using Review Manager 5.1. We calculated standardized mean differences and 95% confidence intervals (CI). Some studies compared two chronic pain samples to a single nonclinical comparison sample. In such cases, we extracted each of these comparisons separately and halved the n of the nonclinical sample to prevent inflating the weight of the individual study. For total alexithymia scores, we included in our analyses any alexithymia measure and scoring convention. However, for alexithymia subscale analyses, we examined only the TAS-20, given that this was the most commonly used measure, and other measures have different factor structures.

For Aim 3, we meta-analyzed correlations of alexithymia with pain intensity, physical interference, depression, and anxiety using random effects models. Finally, for our secondary analysis, we meta-analyzed partial correlations that examined the relationship between alexithymia and pain intensity and physical interference when controlling for measures of negative affect, using random effects models. Meta-analyses of correlation coefficients were conducted in STATA using the DerSinonian-Laird random effects method. We examined effect size and 95% CIs. When there were more than eight studies in a meta-analysis, trim and fill analyses were used to detect publication bias using Duval and Tweedie's [27] method and Rosenthal's failsafe N (1979). Trim and fill analyses evaluate the overall effect and variance of each study included in a meta-analysis, identifies possible missing studies that may have resulted

from publication bias (e.g., selective publication of statistically significant results), and imputes values for these missing studies [27]. We subsequently re-ran meta-analyses to ensure significant findings were not the result of publication bias.

For all meta-analyses, we considered between-study heterogeneity (I^2), and interpreted findings using Cochrane standards as a guide (Higgins & Green, 2011 [44]). Specifically, we adopted the following cut-offs for describing heterogeneity: (0-29% low heterogeneity; 30-49% moderate heterogeneity; 50-74% substantial heterogeneity; 75-100% considerable heterogeneity). To explore whether variability in study quality influenced study findings, we conducted correlations between effect size estimates and quality ratings for analyses of group differences in alexithymia, and for analyses of correlations of alexithymia with pain intensity, physical interference, depression, and anxiety.

Results

Study Selection

Our systematic search resulted in 1,240 abstracts. After screening these abstracts, we identified 157 full texts to review for eligibility. Through review, we excluded 80 studies (see Figure 1). This resulted in 77 full studies for analysis. Among these 77 studies, ten reported data from distinct chronic pain samples (e.g., a study reported data from two distinct samples of individuals with an autoimmune disease and headache). We preserved data from these distinct samples, and therefore included a total of 87 chronic pain samples in our review. We use the terminology "study" to identify overarching studies, or articles, and the terminology "sample" to identify a distinct group of individuals with chronic pain.

Missing Data

We contacted 71 authors to request additional data and analyses. Additional data were obtained for 22 studies. Authors of an additional 17 studies responded but could not complete the request because they lacked access to the original data (n=12) or their schedules were too busy (n=5).

Study Characteristics

From the 77 studies, there were data from 82 adult and 5 youth chronic pain samples (Table 1). Of note, one additional study examined a mixed sample of adolescents and young adults (aged 16-20 years) with inflammatory bowel disease or irritable bowel syndrome [46]. Developmentally, alexithymia scores in individuals within this age range are more similar to adults [97] and therefore we categorized this study as an adult sample.

From 82 adult samples (across 77 studies), data were available on alexithymia mean scores or clinical cut-off scores from 74 (90%), comparison of alexithymia scores of a chronic pain sample to a comparison sample from 34 (41%), zero-order correlations between alexithymia and pain intensity, physical interference, depression and/or anxiety from 40 (49%), and partial correlations from 14 (17%). From 5 youth samples (across 5 studies), we obtained alexithymia mean scores or clinical cut-off scores from four; correlations between alexithymia and key variables of interest from two; and group differences between a chronic pain and comparison sample from one. There were not enough extractable data in studies of youth to conduct meta-analyses. All included studies used some variation of the Toronto Alexithymia Scale, including the TAS-26 (k=14), TAS-20 (k=72), and Alexithymia Questionnaire for Children (AQC; k=1). In this case, the AQC was scored using the same scale as the TAS-20 (i.e., 20-100). Other psychometrically-sound self-report measures (e.g., Bermond-Vorst Alexithymia Questionnaire

[130]) or clinician-administered measures (e.g., Toronto Structured Interview for Alexithymia [7]) of alexithymia were not utilized in this body of literature.

Pooled means and prevalence of alexithymia in individuals with chronic pain

Among the 82 samples of adults with chronic pain, TAS-20 total scores were available for 61, and TAS-26 total scores available for nine. The pooled means of TAS-26 total and TAS-20 total and subscale scores are presented in Table 2. In addition to total scores, the percentage of individuals with a total alexithymia score beyond the clinical cut-off score for TAS-20 was available for 39 samples (n=4092). Of these, 28% of adults with chronic pain exceeded this threshold. The percentage of individuals with a total alexithymia score beyond the clinical cut-off scores for TAS-20 was available for five samples (n=460); of these, 36% of adults exceeded this threshold.

Two studies including youth reported mean alexithymia using a standard scoring convention: Gatta et al. (2011) measured alexithymia using the AQC in a sample of 32 youth with tension-type headache and reported a mean total score of 58.13 (SD = 10.64). Cerutti et al. (2016) assessed alexithymia with the TAS-20 in 53 youth with migraines and reported a mean total score of 56.3 (SD = 12.14); 31% of the youth exceeded clinical cutoffs for alexithymia. These data should be interpreted with caution, however, as the validity of applying adult-derived clinical cutoff scores to characterize alexithymia in youth has been questioned [97].

Group differences in alexithymia in pain versus comparison groups.

We examined group differences in alexithymia total scores in adults with chronic pain (n=1706) compared to non-clinical comparison samples (n=1370; k=27). We also examined four studies that compared alexithymia total scores in adults with chronic pain (n=170) compared to non-pain clinical comparison samples (n=207). One study in the latter analysis was an outlier, reporting an

unexpectedly large effect size difference in alexithymia and was excluded from analyses [103]. A significant and large group difference in total alexithymia between adults with chronic pain and non-clinical comparison samples remained (d = 0.81, 95% CI 0.62, 1.00), although with substantial heterogeneity ($I^2 = 83\%$). Among studies that compared alexithymia total scores in adults with chronic pain to non-pain clinical comparison samples (k=4), there was a statistically significant medium sized effect (d = 0.55, 95% CI 0.34, 0.77) with no observed heterogeneity ($I^2 = 0\%$). A forest plot depicting group differences in alexithymia total scores is presented in Figure 2.

We also examined group differences in alexithymia subscale scores (see Table 3). Adults with chronic pain had greater difficulty identifying feelings scores compared to non-clinical samples, and this was statistically significant with a large effect size. Adults with chronic pain had greater difficulty describing feelings compared to non-clinical samples with a medium effect size. Findings were similar for group differences between adults with chronic pain and non-pain clinical comparison samples. There was no statistically significant group difference in externally-oriented thinking between adults with chronic pain and non-clinical samples. There were too few studies to examine group differences in externally-oriented thinking between adults with chronic and non-pain clinical samples, as well as group differences in alexithymia total and subscale scores in youth.

Relationships of alexithymia with pain intensity, physical interference, depression, and anxiety within pain samples

As shown in Table 4, we found significant, small magnitude, positive correlations between alexithymia and pain intensity and pain interference, and significant, medium-size magnitude, positive relationships between alexithymia and depression and anxiety. Across all analyses,

difficulty identifying feelings was the most strongly associated alexithymia subscale with these measures, followed by difficulty describing feelings. Small relationships were observed between externally-oriented thinking and all variables except pain interference. Trim and fill analyses identified missing studies in just one analysis (relationship between externally-oriented thinking and depression). When missing studies were subsequently filled, the pattern of significance remained the same.

Only two studies examined these correlations in youth; thus meta-analyses for youth could not be conducted. One study showed a significant positive relationship between alexithymia and anxiety, and a nonsignificant relationship between alexithymia and depression [110] in a small sample (n=21) of youth with mixed headache and abdominal pain. The other study showed significant correlations between alexithymia and anxiety and depression in a sample of youth with migraine [18].

Meta-analysis of partial correlations controlling for psychological distress.

Partial correlations between alexithymia and pain measures (intensity and interference) were published in only three studies, and we obtained unpublished data from authors of 11 additional studies (thus, k=14). We meta-analyzed partial correlations between alexithymia (total and subscale scores), pain intensity and pain interference while controlling for negative affect. As shown in Table 5, there were no significant partial correlations of alexithymia total or subscale scores with pain intensity and pain interference.

Quality Assessment

Overall quality ratings are depicted in Figure 3, offering a relative assessment of the overall quality of included studies. For studies of adults, quality ratings ranged from 2 to 8 (mean = 5.13, SD = 1.21; median = 5). For youth studies, quality ranged from 3 through 6 (mean = 4.60,

median = 5). Study quality was not significantly correlated with effect size for group differences in alexithymia (r = .13, p = .429) or correlations of alexithymia with pain intensity (r = -0.21, p = .282), physical interference (r = .20, p = .403), depression (r = .29, p = .138) or anxiety (r = 0.10, p = .650).

Discussion

This is the first systematic review and meta-analysis of alexithymia in individuals with chronic pain. We identified a large number of articles (k = 77), reflecting substantial interest in the assessment of alexithymia, primarily in adults, with a range of pain conditions. Overall, our findings demonstrated that alexithymia was higher in individuals with chronic pain compared to both non-clinical samples (large effect) as well as clinical samples without pain (medium effect). The latter finding suggests that the elevated alexithymia is not solely a bias associated with health care seeking or having a chronic illness. We found that 26% of adults with chronic pain met the threshold of a clinical cutoff score for alexithymia—an estimate that is higher than the 13% reported in the general population [108]. In addition to elevated alexithymia in people with chronic pain, our meta-analyses indicated that, among adults with chronic pain, alexithymia was associated with greater pain intensity and physical interference, with correlations that were small in magnitude. Alexithymia was also positively associated with depression and anxiety, with correlations that were medium in magnitude.

Among adults with chronic pain, greater alexithymia was associated with greater pain intensity and physical interference, with small magnitude effect sizes. These findings are consistent with laboratory-based studies demonstrating altered pain processing in relation to heightened alexithymia in healthy adults [47; 54; 92]. As expected, alexithymia was associated with greater depression and anxiety with large effect sizes. Emotional awareness is important for

effective emotion regulation [40; 56], and alexithymia is associated with reliance on ineffective approaches to emotion regulation including suppression and avoidance [96; 117]. The experience of chronic pain confers additional stress in many life domains (e.g., social, emotional, physical) [121]; in the face of these stressors, alexithymia may be associated with greater difficulty regulating emotions, contributing to poor mental health outcomes [71].

Specific subscales of alexithymia measures showed differential effects; in particular effects were larger for difficulty identifying feelings and difficulty describing feelings, but lower or nonsignificant for externally-oriented thinking. Contributing to this pattern may be the weak psychometric properties of the externally-oriented thinking subscale of the TAS-20 [60], particularly in non-Western cultures [21]. It is also possible that chronic pain is more tightly linked to the constructs of difficulty identifying and describing feelings. With the inability to identify or describe one's emotions, it is possible that awareness of or attention to interoceptive cues is associated with misinterpreting emotional cues as harmful or as signs of illness [72; 119]. Our review highlights the important need for future research on the conceptualization and assessment of emotional awareness as it applies to chronic pain.

We meta-analyzed partial correlations from 14 studies that examined relationships of alexithymia to pain intensity and pain interference while controlling for psychological distress. These analyses revealed that alexithymia was no longer uniquely related to pain variables. There are several possible interpretations of these results. First, some scholars have questioned the validity of self-reported alexithymia, especially given its convergence with measures of negative affect [64; 69], which could spuriously inflate alexithymia's correlations with self-reported measures of pain and other symptoms. Relatedly, individuals with depressive symptoms are more likely to evaluate themselves and their abilities negatively on a self-report survey [64; 69].

Another intriguing possibility is that distress or negative affect may mediate the links between alexithymia and pain. Unfortunately, cross-sectional analyses such as those in the current review cannot differentiate these two possibilities. We also note that potential confounding by negative affect is by no means limited to studies of alexithymia; such bias complicates the assessment and interpretation of many or most self-reported psychological constructs that are related to pain [116; 131]. It should also be noted that only three of the 14 sets of partial correlations that we meta-analyzed had been peer-reviewed and published; the other 11 were provided to us directly by the authors at our request. Given these considerations, we suggest caution in making conclusions about the role of negative affect in the relationship between alexithymia and pain based on the current findings. Of note, the fact that partial correlation analyses were available but rarely published raises the issue of a publication bias in scientific literature towards positive findings [106]. Moving forward, we recommend that investigators examine and report the role of negative affect in the relationship between alexithymia or other psychological constructs and chronic pain, and to test alternative models (e.g., moderation, mediation) to better parse these relationships.

Results from the present systematic review and meta-analysis reveal many significant gaps in this large body of literature. For example, only 5 studies examined alexithymia in youth with chronic pain, and it is unclear whether this construct can be adequately measured in youth. These studies typically applied adult-derived alexithymia cutoff scores, not considered valid in youth populations [138]. Data were insufficient to examine group differences and correlations in youth with chronic pain. Future studies are needed to clarify the role of emotional awareness in youth with pain, using age-appropriate assessment (cf. [138]), to determine how it relates to pain intensity, physical interference, depression and anxiety. Adolescence is a critical window for the

development of emotional insight and emotion regulation (Somerville, 2016). Clarifying the role of emotional awareness in youth with pain may have developmental implications and unique treatment considerations.

Another gap in the broad alexithymia and chronic pain literature is the preponderance of cross-sectional study designs. Very few studies in this field have examined temporal patterns or longitudinal relationships between alexithymia and chronic pain. Alexithymia may be a risk factor for subsequent pain where reduced ability to label and describe emotions leads to misperceptions of the physiological correlates of emotion as signs of illness [63; 73; 118]. On the other hand, chronic pain may contribute to affective deficits observed in alexithymia.

Constructivist theories of emotion argue that the subjective experience of emotion results in part from awareness of bodily cues [9]. A recent systematic review concluded that individuals with chronic pain have reduced accuracy in detecting interoceptive cues compared to comparison samples [22]. The presence of pain, a potentially threatening biological cue, may distract from awareness of relevant interoceptive cues, particularly those subtle cues involved in daily experiences and interactions with others. This is an empirical question for future research.

Addressing these gaps in the literature has potential implications for clinical intervention. It is possible that individuals with both chronic pain and elevated alexithymia may benefit from interventions that directly target processes related to emotional awareness, such as emotional awareness and expression training [75]. On the other hand, more general psychological interventions may function to reduce depression and anxiety, and in turn result in reduced alexithymia. Future research is needed to investigate ontological distinctions between alexithymia and negative affect, and if and how they relate temporally.

Current findings should be considered in light of additional limitations. There is substantial debate about the alexithymia construct more broadly. Alexithymia generally, and the TAS-20 specifically, has been criticized for relying on Western norms, which value individual emotional experience and verbal expression of emotion [58]. Diverging from this norm may indicate psychopathology in Western culture, but not necessarily in others. Nonetheless, a strength of the current meta-analysis is representation from many different geographic regions and cultures, and the TAS-20 has been validated in a number of Eastern cultures [87; 137]. Future studies should examine whether ethnicity or culture moderate the relationship between alexithymia and chronic pain. Another limitation of the TAS-20, particularly the difficulty identifying feelings subscale, is that it contains items pertaining to physiological sensations (e.g., "I have physical sensations that even doctors don't understand;" "I am often puzzled by sensations in my body."). Such items likely reflect the experience of chronic pain, artificially inflating correlations between the TAS-20 and pain-related measures. A number of interview or observer-based measures of alexithymia have been developed, though unfortunately we did not identify studies that made use of these assessment tools in the current meta-analysis.

Meta-analyses in the current study were generally characterized by substantial heterogeneity and thus should be interpreted with caution. There may be relevant demographic or clinical differences that contribute to such heterogeneity. For example, the relationship of alexithymia to pain severity and interference may vary by sex or ethnicity [21; 93] as well as be a function of pain characteristics, such as duration of pain or specific pain condition. The examination of demographic and clinical moderators was beyond the scope of the present meta-analysis and represent potential future avenues of research.

We examined study quality using general criteria and assigned a relative quality value to each included study. The overall mean and median quality score of included studies were relatively high; however, a large subset of studies was characterized by low study quality. Future studies with rigorous methodology and reporting are needed to increase confidence in this body of work. Relative areas of weakness include failing to provide sample size justification and to report participation rates. In addition, very few studies tested the unique validity of alexithymia measures by controlling for various potential confounds: future studies should consider accounting for demographic (e.g., education, age) and clinical factors (e.g., psychological distress) that relate differentially to alexithymia scores.

In conclusion, this systematic review helps summarize a substantial literature examining alexithymia in chronic pain, finding that alexithymia is elevated in youth and adults with chronic pain conditions. In adults, alexithymia is associated with greater pain intensity, physical interference, depression and anxiety. Alexithymia may be relevant to the presence and severity of chronic pain and associated mental health symptoms. Future empirical research is needed to better illuminate these relationships and clarify the potentially confounding role of negative affect. In particular, utilizing prospective designs and non-self-repot alexithymia assessment tools would add greater clarity to this construct and inform development of targeted interventions.

Acknowledgments

We have no conflicts to disclose. We thank the many researchers who contributed additional data upon our request, allowing for a more comprehensive review. These authors are indicated in Table1. We thank Mark Jensen for his assistance on this study's protocol. Rachel Aaron was

supported by NIH T32GM086270 awarded to Tonya Palermo; Tonya Palermo is supported by NIH K24HD060068.

References

- [1] Ak I, Sayar K, Yontem T. Alexithymia, somatosensory amplification and counterdependency in patients with chronic pain. The Pain Clinic 2004;16(1):43-51.
- [2] Asmundson GJ, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety 2009;26(10):888-901.
- [3] Atagun MI, Atagun Z, Evren C, Balaban OD, Yalcinkaya EY, Ones K. Mental symptoms are related with impact of the disease and impairment in quality of life in female patients with fibromyalgia. Dusunen Adam 2012;25(4):338-344.
- [4] Baeza-Velasco C, Carton S, Almohsen C, Blotman F, Gely-Nargeot MC. Alexithymia and emotional awareness in females with painful rheumatic conditions. J Psychosom Res 2012;73(5):398-400.
- [5] Bagby M, Taylor GJ, Ryan DJP, Psychosomatics. Toronto Alexithymia Scale: Relationship with personality and psychopathology measures. 1986;45(4):207-215.
- [6] Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia Scale—I. Item selection and cross-validation of the factor structure. J Psychosom Res 1994;38(1):23-32.
- [7] Bagby RM, Taylor GJ, Parker JD, Dickens SE. The development of the Toronto Structured Interview for Alexithymia: item selection, factor structure, reliability and concurrent validity. Psychother Psychosom 2006;75(1):25-39.
- [8] Balaban H, Semiz M, Senturk IA, Kavakci O, Cinar Z, Dikici A, Topaktas S. Migraine prevalence, alexithymia, and post-traumatic stress disorder among medical students in Turkey. The Journal of Headache and Pain 2012;13(6):459-467.

- [9] Barrett LF. Are emotions natural kinds? Perspect Psychol Sci 2006;1(1):28-58.
- [10] Baudic S, Jayr C, Albi-Feldzer A, Fermanian J, Masselin-Dubois A, Bouhassira D, Attal N. Effect of alexithymia and emotional repression on postsurgical pain in women with breast cancer: A prospective longitudinal 12-month study. The Journal of Pain 2016;17(1):90-100.
- [11] Bornemann B, Singer T. Taking time to feel our body: Steady increases in heartbeat perception accuracy and decreases in alexithymia over 9 months of contemplative mental training. Psychophysiology 2017;54(3):469-482.
- [12] Burger AJ, Lumley MA, Carty JN, Latsch DV, Thakur ER, Hyde-Nolan ME, Hijazi AM, Schubiner H. The effects of a novel psychological attribution and emotional awareness and expression therapy for chronic musculoskeletal pain: A preliminary, uncontrolled trial. J Psychosom Res 2016:1-8.
- [13] Burger AJ, Lumley MA, Carty JN, Latsch DV, Thakur ER, Hyde-Nolan ME, Hijazi AM, Schubiner H. The effects of a novel psychological attribution and emotional awareness and expression therapy for chronic musculoskeletal pain: A preliminary, uncontrolled trial. J Psychosom Res 2016;81:1-8.
- [14] Burke AL, Mathias JL, Denson LA. Psychological functioning of people living with chronic pain: A meta-analytic review. Br J Clin Psychol 2015;54(3):345-360.
- [15] Cameron, Ogrodniczuk J, Hadjipavlou G. Changes in alexithymia following psychological intervention: a review. Harv Rev Psychiatry 2014;22(3):162-178.
- [16] Castelli L, Tesio V, Colonna F, Molinaro S, Leombruni P, Bruzzone M, Fusaro E, Sarzi-Puttini P, Torta R. Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. Clin Exp Rheumatol 2012;30(6 Suppl 74):70-77.

- [17] Castelli L, Tesio V, Di Tella M, Colonna F, Ghiggia A, Cagna M, Leombruni P, Fusaro E, Torta R. Alexithymia, pain and depression in fibromyalgia syndrome. Psychother Psychosom 2013;82:17-18.
- [18] Cerutti R, Valastro C, Tarantino S, Valeriani M, Faedda N, Spensieri V, Guidetti V. Alexithymia and psychopathological symptoms in adolescent outpatients and mothers suffering from migraines: a case control study. J Headache Pain 2016;17 (1) (no pagination)(39).
- [19] Chang MC, Chen PF, Lung FW. Personality disparity in chronic regional and widespread pain. Psychiatry Res 2017;254:284-289.
- [20] Cologno D, Buzzi M, Carlesimo G, Cicinelli P, Costa A, Fadda L, Formisano R, Marconi B, Pero S, Caltagirone C. Psychiatric disorders and pain location in unilateral migraineurs. The Journal of Headache and Pain 2005;6(4):227-230.
- [21] Dere J, Tang Q, Zhu X, Cai L, Yao S, Ryder AG. The cultural shaping of alexithymia: values and externally oriented thinking in a Chinese clinical sample. Compr Psychiatry 2013;54(4):362-368.
- [22] Di Lernia D, Serino S, Riva G. Pain in the body. Altered interoception in chronic pain conditions: A systematic review. Neurosci Biobehav Rev 2016;71:328-341.
- [23] Di Tella M, Castelli L. Alexithymia in chronic pain disorders. Curr Rheumatol Rep 2016;18(7):41.
- [24] Di Tella M, Ghiggia A, Tesio V, Romeo A, Colonna F, Fusaro E, Torta R, Castelli L. Pain experience in fibromyalgia syndrome: The role of alexithymia and psychological distress.

 J Affect Disord 2017:87-93.

- [25] Di Tella M, Ghiggia A, Tesio V, Romeo A, Colonna F, Fusaro E, Torta R, Castelli L. Pain experience in Fibromyalgia Syndrome: The role of alexithymia and psychological distress. J Affect Disord 2017;208:87-93.
- [26] Duruk B, Sertel Berk HO, Ketenci A. Are fibromyalgia and failed back surgery syndromes actually "functional somatic syndromes" in terms of their symptomatological, familial and psychological characteristics? A comparative study with chronic medical illness and healthy controls. Agri: Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 2015;27(3):123-131.
- [27] Duval S, Tweedie R. Trim and fill: a simple funnel-plot—based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455-463.
- [28] Esin O, Gorobets E, Khairullin I, Esin R. Alexithymia as a Predictor of Chronic Tension Headaches. BioNanoScience 2017;7(2):272-275.
- [29] Evren B, Evren C, Guler MH. Clinical correlates of alexithymia in patients with fibromyalgia. The Pain Clinic 2006;18(1):1-9.
- [30] Fernandez A, Sriram T, Rajkumar S, Chandrasekar A. Alexithymic characteristics in rheumatoid arthritis: A controlled study. Psychother Psychosom 1989;51(1):45-50.
- [31] Galli F, Caputi M, Sances G, Vegni E, Bottiroli S, Nappi G, Tassorelli C. Alexithymia in chronic and episodic migraine: a comparative study. Journal of Mental Health 2017;26(3):192-196.
- [32] Gaskin DJ, Richard P. The economic costs of pain in the United States. The Journal of Pain 2012;13(8):715-724.

- [33] Gatta M, Canetta E, Zordan M, Spoto A, Ferruzza E, Manco I, Addis A, Dal Zotto L, Toldo I, Sartori S, Battistella PA. Alexithymia in juvenile primary headache sufferers: A pilot study. The Journal of Headache and Pain 2011;12(1):71-80.
- [34] Gatta M, Spitaleri C, Balottin U, Spoto A, Balottin L, Mangano S, Battistella PA.

 Alexithymic characteristics in pediatric patients with primary headache: a comparison between migraine and tension-type headache. J Headache Pain 2015;16(1):1-7.
- [35] Ghiggia A, Romeo A, Tesio V, Tella MD, Colonna F, Geminiani GC, Fusaro E, Castelli L. Alexithymia and depression in patients with fibromyalgia: When the whole is greater than the sum of its parts. Psychiatry Res 2017;255:195-197.
- [36] Glaros AG, Lumley MA. Alexithymia and pain in temporomandibular disorder. J Psychosom Res 2005;59(2):85-88.
- [37] Gregory RJ, Manring J, Berry SL. Pain location and psychological characteristics of patients with chronic pain. Psychosomatics: Journal of Consultation and Liaison Psychiatry 2000;41(3):216-220.
- [38] Gregory RJ, Manring J, Wade MJ. Personality Traits Related to Chronic Pain Location. Ann Clin Psychiatry 2005;17(2):59-64.
- [39] Groenewald CB, Essner BS, Wright D, Fesinmeyer MD, Palermo TM. The economic costs of chronic pain among a cohort of treatment-seeking adolescents in the United States.

 The Journal of Pain 2014;15(9):925-933.
- [40] Gross JJ. Emotion regulation: Current status and future prospects. Psychol Inq 2015;26(1):1-26.
- [41] Gross JJJPI. The extended process model of emotion regulation: Elaborations, applications, and future directions. 2015;26(1):130-137.

- [42] Gulec H. Normalizing attributions may contribute to non-help-seeking behavior in people with fibromyalgia syndrome. Psychosomatics 2008;49(3):212-217.
- [43] Haas J, Eichhammer P, Traue HC, Hoffmann H, Behr M, Cronlein T, Pieh C, Busch V.

 Alexithymic and somatisation scores in patients with temporomandibular pain disorder correlate with deficits in facial emotion recognition. J Oral Rehabil 2013;40(2):81-90.
- [44] Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, Vol. 4: John Wiley & Sons, 2011.
- [45] Hosoi M, Molton IR, Jensen MP, Ehde DM, Amtmann S, O'Brien S, Arimura T, Kubo C. Relationships among alexithymia and pain intensity, pain interference, and vitality in persons with neuromuscular disease: Considering the effect of negative affectivity. Pain 2010;149(2):273-277.
- [46] Huang JS, Terrones L, Simmons AN, Kaye W, Strigo I. Pilot Study of Functional Magnetic Resonance Imaging Responses to Somatic Pain Stimuli in Youth With Functional and Inflammatory Gastrointestinal Disease. J Pediatr Gastroenterol Nutr 2016;63(5):500-507.
- [47] Huber A, Suman AL, Biasi G, Carli G. Alexithymia in fibromyalgia syndrome:

 Associations with ongoing pain, experimental pain sensitivity and illness behavior.

 Journal of Psychosomatic Research 2009;66(5):425-433.
- [48] Huguet A, Miró J. The severity of chronic pediatric pain: an epidemiological study. The Journal of Pain 2008;9(3):226-236.
- [49] Jasinski MJ, Lumley MA, Latsch DV, Schuster E, Kinner E, Burns JW. Assessing anger expression: Construct validity of three emotion expression-related measures. J Pers Assess 2016;98(6):640-648.

- [50] Jerjes W, Madland G, Feinmann C, Hopper C, Kumar M, Upile T, Kudari M, Newman S. A psychological comparison of temporomandibular disorder and chronic daily headache: are there targets for therapeutic interventions? Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2007;103(3):367-373.
- [51] Jerlang BB. Burning mouth syndrome (BMS) and the concept of alexithymia A preliminary study. J Oral Pathol Med 1997;26(6):249-253.
- [52] Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. The Journal of Pain 2010;11(11):1230-1239.
- [53] Johannsen M, O'Toole MS, O'Connor M, Jensen AB, Zachariae R. Clinical and psychological moderators of the effect of mindfulness-based cognitive therapy on persistent pain in women treated for primary breast cancer-explorative analyses from a randomized controlled trial. Acta Oncol 2017;56(2):321-328.
- [54] Kano M, Hamaguchi T, Itoh M, Yanai K, Fukudo S. Correlation between alexithymia and hypersensitivity to visceral stimulation in human. Pain 2007;132(3):252-263.
- [55] Karahan AY, Kucuk A, Balkarli A, Kayhan F, Ozhan N, Nas O, Gungor T, Kucuksen S. Alexithymia, depression, anxiety levels and quality of life in patients with rheumatoid arthritis. Acta Medica Mediterranea 2016;32(5):1675-1682.
- [56] Kashdan TB, Barrett LF, McKnight PE. Unpacking emotion differentiation transforming unpleasant experience by perceiving distinctions in negativity. Curr Dir Psychol Sci 2015;24(1):10-16.

- [57] King S, Chambers CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, MacDonald AJ.

 The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain 2011;152(12):2729-2738.
- [58] Kirmayer LJJTPRR. Languages of suffering healing: Alexithymia as a social and cultural process. 1987;24(2):119-136.
- [59] Kojima M, Kojima T, Suzuki S, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Hirabara S, Asai S, Ishiguro N. Alexithymia, depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Care Res 2014;66(5):679-686.
- [60] Kooiman C, Spinhoven P, Trijsburg R. The assessment of alexithymia: a critical review of the literature and a psychometric study of the Toronto Alexithymia Scale-20. J Psychosom Res 2002;53(6):1083-1090.
- [61] Kosturek A, Gregory RJ, Sousou AJ, Trief P. Alexithymia and somatic amplification in chronic pain. Psychosomatics: Journal of Consultation and Liaison Psychiatry 1998;39(5):399-404.
- [62] Kugu N, Kaptanoglu E, Kavakci O, Guler E. Psychopathology, family functioning and marital relationship in female patients with fibromyalgia syndrome. Neurology Psychiatry and Brain Research 2009;16(3-4):83-90.
- [63] Lane RD, Schwartz GE. Levels of emotional awareness: A cognitive-developmental theory and its application to psychopathology. The American journal of psychiatry 1987.
- [64] Leising D, Grande T, Faber R. The Toronto Alexithymia Scale (TAS-20): A measure of general psychological distress. Journal of Research in Personality 2009;43(4):707-710.
- [65] Leweke F, Leichsenring F, Kruse J, Hermes S. Is alexithymia associated with specific mental disorders. Psychopathology 2011;45(1):22-28.

- [66] Li S, Zhang B, Guo Y, Zhang J. The association between alexithymia as assessed by the 20item Toronto Alexithymia Scale and depression: A meta-analysis. Psychiatry Res 2015;227(1):1-9.
- [67] Lieberman MD, Eisenberger NI, Crockett MJ, Tom SM, Pfeifer JH, Way BM. Putting feelings into words. Psychol Sci 2007;18(5):421-428.
- [68] Lieberman MD, Inagaki TK, Tabibnia G, Crockett MJ. Subjective responses to emotional stimuli during labeling, reappraisal, and distraction. Emotion 2011;11(3):468.
- [69] Lumley MA. Alexithymia and negative emotional conditions. 2000.
- [70] Lumley MA, Asselin LA, Norman S. Alexithymia in chronic pain patients. Compr Psychiatry 1997;38(3):160-165.
- [71] Lumley MA, Beyer J, Radcliffe A. Alexithymia and physical health problems: a critique of potential pathways and a research agenda. Emotion Regulation: Springer, 2008. pp. 43-68.
- [72] Lumley MA, Cohen JL, Borszcz GS, Cano A, Radcliffe AM, Porter LS, Schubiner H, Keefe FJ. Pain and emotion: a biopsychosocial review of recent research. J Clin Psychol 2011;67(9):942-968.
- [73] Lumley MA, Neely LC, Burger AJ. The assessment of alexithymia in medical settings: implications for understanding and treating health problems. J Pers Assess 2007;89(3):230-246.
- [74] Lumley MA, Radcliffe AM, Macklem DJ, Mosley-Williams A, Leisen JCC, Huffman JL, D'Souza PJ, Gillis ME, Meyer TM, Kraft CA, Rapport LJ. Alexithymia and pain in three chronic pain samples: Comparing Caucasians and African Americans. Pain Med 2005;6(3):251-261.

- [75] Lumley MA, Schubiner H, Lockhart NA, Kidwell KM, Harte SE, Clauw DJ, Williams DA.

 Emotional awareness and expression therapy, cognitive behavioral therapy, and
 education for fibromyalgia: a cluster-randomized controlled trial. Pain
 2017;158(12):2354-2363.
- [76] Lumley MA, Smith JA, Longo DJ. The relationship of alexithymia to pain severity and impariment among patients with chronic myofascial pain: Comparisons with self-efficacy, catastrophizing and depression. J Psychosom Res 2002;53(3):823-830.
- [77] Makino S, Jensen MP, Arimura T, Obata T, Anno K, Iwaki R, Kubo C, Sudo N, Hosoi M. Alexithymia and chronic pain: The role of negative affectivity. The Clinical Journal of Pain 2013;29(4):354-361.
- [78] Margalit D, Ben Har L, Brill S, Vatine JJ. Complex regional pain syndrome, alexithymia, and psychological distress. J Psychosom Res 2014;77(4):273-277.
- [79] Marino R, Picci RL, Ferro G, Carezana C, Gandolfo S, Pentenero M. Peculiar alexithymic traits in burning mouth syndrome: case-control study. Clin Oral Investig 2015;19(8):1799-1805.
- [80] Martinez M, Sanchez AI, Miro E, Lami MJ, Prados G, Morales A. Relationships between physical symptoms, emotional distress, and pain appraisal in fibromyalgia: The moderator effect of alexithymia. The Journal of Psychology: Interdisciplinary and Applied 2015;149(2):115-140.
- [81] Melin EO, Thulesius HO, Persson BA. Affect School for chronic benign pain patients showed improved alexithymia assessments with TAS-20. BioPsychoSocial Medicine Vol 4 2010, ArtID 5 2010.

- [82] Melis I, Agus M, Pluchino N, Di Spiezio Sardo A, Litta P, Melis GB, Angioni S.

 Alexithymia in women with deep endometriosis? A pilot study. Journal of Endometriosis and Pelvic Pain Disorders 2014;6(1):26-33.
- [83] Millard RW, Kinsler BL. Evaluation of constricted affect in chronic pain: An attempt using the Toronto Alexythymia Scale. Pain 1992;50(3):287-292.
- [84] Mingarelli A, Casagrande M, Di Pirchio R, Nizzi S, Parisi C, Loy BC, Solano L, Rampello A, Di Paolo C. Alexithymia partly predicts pain, poor health and social difficulties in patients with temporomandibular disorders. J Oral Rehabil 2013;40(10):723-730.
- [85] Miyaoka H, Kamijima K, Katayama Y, Ebihara T, Nagai T. A psychiatric appraisal of "glossodynia.". Psychosomatics: Journal of Consultation and Liaison Psychiatry 1996;37(4):346-348.
- [86] Montoro CI, Reyes del Paso GA, Duschek S. Alexithymia in fibromyalgia syndrome. Pers Individ Dif 2016:170-179.
- [87] Moriguchi Y, Maeda M, Igarashi T, Ishikawa T, Shoji M, Kubo C, Komaki GJBm. Age and gender effect on alexithymia in large, Japanese community and clinical samples: a cross-validation study of the Toronto Alexithymia Scale (TAS-20). 2007;1(1):7.
- [88] Muftuoglu MN, Herken H, Demirci H, Virit O, Neyal A. Alexithymic features in migraine patients. Eur Arch Psychiatry Clin Neurosci 2004;254(3):182-186.
- [89] Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. The Journal of Pain 2015;16(8):769-780.
- [90] National Heart L, Institute B. Quality assessment tool for observational cohort and cross-sectional studies. Bethesda, MD: National Institutes of Health, Department of Health and Human Services 2014.

- [91] Noel M, Groenewald CB, Beals-Erickson SE, Gebert JT, Palermo TM. Chronic pain in adolescence and internalizing mental health disorders: A nationally representative study. Pain 2016;157(6):1333-1338.
- [92] Nyklíček I, Vingerhoets AJ. Alexithymia is associated with low tolerance to experimental painful stimulation. Pain 2000;85(3):471-475.
- [93] Ogrodniczuk JS, Kealy D, Joyce AS, Abbass AA. Body talk: Sex differences in the influence of alexithymia on physical complaints among psychiatric outpatients. Psychiatry Res 2018.
- [94] Ozturk AB, Ozenli Y, Ozturk SB, Onel S, Soker G, Seydaoglu G. The effect of psychoeducation on anxiety and pain in patients with mastalgia. Nordic Journal of Psychiatry 2015;69(5):380-385.
- [95] Palermo TM. Impact of recurrent and chronic pain on child and family daily functioning: a critical review of the literature. J Dev Behav Pediatr 2000.
- [96] Panayiotou G, Leonidou C, Constantinou E, Hart J, Rinehart KL, Sy JT, Björgvinsson T. Do alexithymic individuals avoid their feelings? Experiential avoidance mediates the association between alexithymia, psychosomatic, and depressive symptoms in a community and a clinical sample. Compr Psychiatry 2015;56:206-216.
- [97] Parker JD, Eastabrook JM, Keefer KV, Wood LM. Can alexithymia be assessed in adolescents? Psychometric properties of the 20-item Toronto Alexithymia Scale in younger, middle, and older adolescents. Psychol Assess 2010;22(4):798.
- [98] Pecukonis EV. Physical self-efficacy and alexithymia in women with chronic intractable back pain. Pain Manag Nurs 2009;10(3):116-123.

- [99] Penacoba Puente C, Velasco Furlong L, Ecija Gallardo C, Cigaran Mendez M, McKenney K. Anxiety, Depression and Alexithymia in Fibromyalgia: Are There Any Differences According to Age? J Women Aging 2013;25(4):305-320.
- [100] Pepe L, Milani R, Di Trani M, Di Folco G, Lanna V, Solano L. A more global approach to musculoskeletal pain: Expressive writing as an effective adjunct to physiotherapy.

 Psychol Health Med 2014;19(6):687-697.
- [101] Porcelli P, De Carne M, Leandro G. Alexithymia and gastrointestinal-specific anxiety in moderate to severe irritable bowel syndrome. Compr Psychiatry 2014;55(7):1647-1653.
- [102] Porcelli P, De Carne M, Leandro G. The role of alexithymia and gastrointestinal-specific anxiety as predictors of treatment outcome in irritable bowel syndrome. Compr Psychiatry 2017;73:127-135.
- [103] Portincasa P, Moschetta A, Baldassare G, Altomare DF, Palasciano G. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROMEII criteria for irritable bowel syndrome. World J Gastroenterol 2003;9(10):2293-2299.
- [104] Rayner L, Hotopf M, Petkova H, Matcham F, Simpson A, McCracken LM. Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs. Pain 2016;157(7):1472.
- [105] Rieffe C, Oosterveld P, Terwogt MM. An alexithymia questionnaire for children: Factorial and concurrent validation results. Pers Individ Dif 2006;40(1):123-133.
- [106] Rosenthal RJPb. The file drawer problem and tolerance for null results. 1979;86(3):638.

- [107] Saariaho AS, Saariaho TH, Mattila AK, Joukamaa MI, Karukivi M. The role of alexithymia: An 8-year follow-up study of chronic pain patients. Compr Psychiatry 2016:145-154.
- [108] Salminen JK, Saarijärvi S, Äärelä E, Toikka T, Kauhanen J. Prevalence of alexithymia and its association with sociodemographic variables in the general population of Finland. J Psychosom Res 1999;46(1):75-82.
- [109] Sayar K, Gulec H, Topbas M. Alexithymia and anger in patients with fibromyalgia. Clin Rheumatol 2004;23(5):441-448.
- [110] Sayin A, Derinoz O, Bodur S, Senol S, Sener S. Psychiatric symptoms and alexithymia in children and adolescents with non-organic pain: A controlled study. Gazi Medical Journal 2007;18(4):170-176.
- [111] Shibata M, Ninomiya T, Jensen MP, Anno K, Yonemoto K, Makino S, Iwaki R, Yamashiro K, Yoshida T, Imada Y, Kubo C, Kiyohara Y, Sudo N, Hosoi M. Alexithymia is associated with greater risk of chronic pain and negative affect and with lower life satisfaction in a general population: The Hisayama study. PLoS One 2014;9 (3) (no pagination)(e90984).
- [112] Sifneos PE. The prevalence of 'alexithymic' characteristics in psychosomatic patients.

 Psychother Psychosom 1973;22(2-6):255-262.
- [113] Sinikallio S, Aalto T, Airaksinen O, Herno A, Kroger H, Savolainen S, Turunen V, Viinamaki H. Depression and associated factors in patients with lumbar spinal stenosis.

 Disability and Rehabilitation: An International, Multidisciplinary Journal 2006;28(7):415-422.

- [114] Slavin-Spenny O, Lumley MA, Thakur ER, Nevedal DC, Hijazi AM. Effects of anger awareness and expression training versus relaxation training on headaches: A randomized trial. Ann Behav Med 2013;46(2):181-192.
- [115] Steinweg DL, Dallas AP, Rea WS. Fibromyalgia: Unspeakable suffering, a prevalence study of alexithymia. Psychosomatics: Journal of Consultation and Liaison Psychiatry 2011;52(3):255-262.
- [116] Strand EB, Zautra AJ, Thoresen M, Ødegård S, Uhlig T, Finset AJJopr. Positive affect as a factor of resilience in the pain—negative affect relationship in patients with rheumatoid arthritis. 2006;60(5):477-484.
- [117] Swart M, Kortekaas R, Aleman A. Dealing with feelings: characterization of trait alexithymia on emotion regulation strategies and cognitive-emotional processing. PLoS One 2009;4(6):e5751.
- [118] Taylor GJ, Bagby R, Parker J. Disorders of affect regulation: Alexithymia in medical and psychiatric illness. 10.1017. CBO9780511526831 1997.
- [119] Taylor GJ, Bagby RM. New trends in alexithymia research. Psychother Psychosom 2004;73(2):68-77.
- [120] Taylor GJJTCJoP. Recent developments in alexithymia theory and research. 2000;45(2):134-142.
- [121] Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of psychosocial and functional impact of chronic pain. The Journal of Pain 2016;17(9):T21-T49.
- [122] Tuzer V, Bulut SD, Bastug B, Kayalar G, Goka E, Bestepe E. Causal attributions and alexithymia in female patients with fibromyalgia or chronic low back pain. Nordic Journal of Psychiatry 2011;65(2):138-144.

- [123] Vadacca M, Bruni R, Terminio N, Sambataro G, Margiotta D, Serino FM, Afeltra A. Alexithymia, mood states and pain experience in systemic lupus erythematosus and rheumatoid arthritis. Clin Rheumatol 2014;33(10):1443-1450.
- [124] Valkamo M, Hintikka J, Niskanen L, Viinamaki H. Psychiatric morbidity and the presence and absence of angiographic coronary disease in patients with chest pain. Acta Psychiatr Scand 2001;104(5):391-396.
- [125] van Middendorp H, Lumley MA, Jacobs JW, van Doornen LJ, Bijlsma JW, Geenen R. Emotions and emotional approach and avoidance strategies in fibromyalgia. J Psychosom Res 2008;64(2):159-167.
- [126] Veehof MM, Ten Klooster PM, Taal E, Westerhof GJ, Bohlmeijer ET. Psychometric properties of the Dutch Five Facet Mindfulness Questionnaire (FFMQ) in patients with fibromyalgia. Clin Rheumatol 2011;30(8):1045-1054.
- [127] Vieira RV, Vieira DC, Gomes WB, Gauer G. Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura. The journal of headache and pain 2013;14(1):18.
- [128] Villani V, Bruti G, Mostardini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R. Migraine in the emergency department: A psychometric study of a migraine "repeaters" sample. Journal of Headache and Pain 2005;6(4):301-303.
- [129] Villani V, Di Stani F, Vanacore N, Scattoni L, Cerbo R, Bruti G. The "repeater" phenomenon in migraine patients: A clinical and psychometric study. Headache: The Journal of Head and Face Pain 2010;50(3):348-356.
- [130] Vorst HC, Bermond B. Validity and reliability of the Bermond–Vorst alexithymia questionnaire. Pers Individ Dif 2001;30(3):413-434.

- [131] Watson D, Pennebaker JWJPr. Health complaints, stress, and distress: exploring the central role of negative affectivity. 1989;96(2):234.
- [132] White KS, McDonnell CJ, Gervino EV. Alexithymia and anxiety sensitivity in patients with non-cardiac chest pain. J Behav Ther Exp Psychiatry 2011;42(4):432-439.
- [133] Wise TN, Mann LS, Jani N, Jani S. Illness beliefs and alexithymia in headache patients. Headache: The Journal of Head and Face Pain 1994;34(6):362-365.
- [134] Yalug I, Selekler M, Erdogan A, Kutlu A, Dundar G, Ankarali H, Aker T. Correlations between alexithymia and pain severity, depression, and anxiety among patients with chronic and episodic migraine. Psychiatry Clin Neurosci 2010;64(3):231-238.
- [135] Yucel B, Kora K, Ozyalcin S, Alcalar N, Ozdemir O, Yucel A. Depression, automatic thoughts, alexithymia, and assertiveness in patients with tension-type headache. Headache: The Journal of Head and Face Pain 2002;42(3):194-199.
- [136] Zeng F, Sun X, Yang B, Fu X. Life events, anxiety, social support, personality, and alexithymia in female patients with chronic pain: A path analysis. Asia-Pacific Psychiatry 2016;8(1):44-50.
- [137] Zhu X, Yi J, Yao S, Ryder AG, Taylor GJ, Bagby RMJCP. Cross-cultural validation of a Chinese translation of the 20-item Toronto Alexithymia Scale. 2007;48(5):489-496.
- [138] Zimmermann G, Quartier V, Bernard M, Salamin V, Maggiori C. The 20-item Toronto Alexithymia Scale: Structural validity, internal consistency and prevalence of alexithymia in a Swiss adolescent sample. L'encéphale 2007;33(6):941-946.
- [139] Zincir SB, Sunbul M, Sunbul EA, Dalkilic B, Cengiz F, Kivrak T, Durmus E. Evaluation of alexithymia, somatosensory sensitivity, and health anxiety levels in patients with noncardiac chest pain. BioMed research international 2014;2014:896183.

Figure legends

- Figure 1. PRISMA flow chart diagramming studies included in meta-analyses.
- Figure 2. Summary of quality ratings across all samples (87) included in manuscript.
- Figure 3. Forest plot depicting group differences in alexithymia score between adults with chronic pain and non-clinical and clinical comparison samples.



				pain	Age	Sex		Quality
		Study	Country of	group	(Mean and	(%	Alexithymia	assessment
Study Author and Year	Pain condition	design	study	(N)	SD)	female)	Measure	(0-8)
Adult Studies:								
Ak (2004) [<u>1]</u>	Mixed chronic pain	G,M	Turkey	30	40.6 (11.4)	83%	TAS-20	5
Atagun (2012) [<u>3]</u>	Fibromyalgia	C,M	Turkey	57	40.9 (6.9)	100%	TAS-20	5
Baeza-Velasco (2012) [<u>4</u>]*	Mixed chronic	C,G,M	France	39	52.2 (8.9)	100%	TAS-20	3
Balaban (2012) [<u>8]</u>	Headache	M	Turkey	31	20.9 (1.7)	81%	TAS-20	5
Burger (2012) [12]*	MSK	C,M	USA	72	49.3 (15.6)	79%	TAS-20	8
Castelli (2012) [<u>17</u>]	TMD	C,M	Italy	45	38.9 (11.6)	100%	TAS-20	4
Castelli (2012) [<u>16</u>]	Fibromyalgia	G,M	Italy	55	52.8 (10.5)	100%	TAS-20	4
Cerutti (2016) [<u>18</u>] ^{a*}	Headache	M	Italy	53	41.8 (3.9)	53%	TAS-20	4
Chang (2017) [<u>19</u>] ^a	Chronic pain	G,M	Taiwan	121	54.0 (15.6)	9%	TAS-20	6
Chang (2017) [<u>19</u>] ^a	Fibromyalgia	G,M	Taiwan	58	57.5 (15.8)	71%	TAS-20	6
Cologno (2005) [<u>20</u>]	Headache	M	Italy	35	38.0 (9.3)	80%	TAS-20	3
Di Tella (2017) [<u>24</u>]*	Fibromyalgia	C,M	Italy	159	52.5 (10.2)	100%	TAS-20	6

Duruk (2015) [<u>26</u>]*	Fibromyalgia	C,G,M	Turkey	35	41 (9.7)	100%	TAS-20	6
Esin (2017) [<u>28</u>]	Headache	M	Russia	137	40.8 (6.3)	61%	TAS-26	3
Evren (2006) [<u>29</u>]	Fibromyalgia	C,M	Turkey	51	37.2 (9.3)	100%	TAS-20	6
Fernandez (1989) [<u>30</u>]	Autoimmune	G,M	India	40	36.1 (11.3)	65%	TAS-26	3
Galli (2017) [<u>31</u>]*	Headache	G,M	Italy	80	44.7 (8.6)	74%	TAS-20	5
Ghiggia (2017) [<u>35</u>]*	Fibromyalgia	C,G,M	Italy	181	51.7 (10.2)	100%	TAS-20	5
Glaros (2005) [<u>36</u>]	TMD	C,G,M	USA	49	39.9 (12)	NR	TAS-20	5
Gregory (2000) [<u>37</u>]	Chronic pain	G,M	USA	140	44.7 (11.2)	75%	TAS-20	5
Gregory (2005) [<u>38</u>] ^a	Chronic pain	G,M	USA	46	NR	NR	TAS-20	6
Gregory (2005) [<u>38</u>] ^a	MSK	G,M	USA	49	NR	NR	TAS-20	7
Gulec (2008)* [<u>42</u>]	Fibromyalgia	C,M	Turkey	75	43.6 (10.6)	100%	TAS-20	7
Haas (2013) [<u>43</u>]	TMD	G	Germany	20	40.6 (14.7)	90%	TAS-26	7
Hosoi (2010) [<u>45</u>]	Autoimmune	C	USA	129	52 (12.4)	56%	TAS-20	6
Huang (2016) [<u>46</u>]	Mixed chronic	G,M	USA	20	17 (NR)	55%	TAS-20	5
Huang (2010) [<u>40</u>]	pain	G,M	USA	20	17 (NK)	3370	143-20	J
Huber (2009) [<u>47]</u> *	Fibromyalgia	C,M	Italy	68	43.4 (11.1)	100%	TAS-20	5
Jasinski (2016) [<u>49</u>]	MSK	M	USA	95	46.9 (9.7)	52%	TAS-20	4
Jerjes (2007) [<u>50]</u>	Headache	G,M	UK	51	40 (13)	67%	TAS-20	5
Jerlang (1997) [<u>51</u>]	BMS	M	Denmark	20	67 (NR)	100%	TAS-26	4

Johannsen (2017) [<u>53</u>]*	Cancer	C,M	Denmark	129	56.8 (9.1)	100%	TAS-20	4
Karahan (2016) [<u>55</u>]	Autoimmune	G,M	Turkey	148	52.6 (12.0)	78%	TAS-20	5
Kojima (2014) [<u>59]</u> *	Autoimmune	C,M	Japan	213	60 (12)	82%	TAS-20	7
Kosturek (1998) [<u>61</u>]	MSK	M	USA	50	43.6 (10.9)	46%	TAS-20	6
Kugu (2009) [<u>62]</u>	Fibromyalgia	G,M	Turkey	54	48.1 (8.1)	100%	TAS-20	4
Lumley (1997) [70]	Chronic pain	C,G	USA	30	40.4 (NR)	70%	TAS-26	5
Lumley (2002) [76]*	Myofascial	C,M	USA	80	48.7 (11.8)	75%	TAS-20	6
Lumley (2005) [74] ^a	Autoimmune	C,M	USA	155	55 (NR)	88%	TAS-20	5
Lumley (2005) [74] a	Headache	C,M	USA	160	31.8 (NR)	84%	TAS-20	5
Malring (2012) [77]	Mixed chronic	CM	Jaman	128	F2 2 (1 <i>(</i> -2)	740/	TAS-20	7
Makino (2013) [77]	pain	C,M	Japan	128	52.3 (16.3)	74%	1A5-20	/
Margalit (2014) [78] ^a	CRPS	C,M	Israel	30	38.3 (14.3)	40%	TAS-20	5
Margalit (2014) [78] ^a	MSK	C,M	Israel	30	38.2 (12.5)	40%	TAS-20	5
Marino (2015) [79]	BMS	C,G,M	Italy	58	65.6 (10.5)	79%	TAS-20	4
Martínez (2015) [80]*	Fibromyalgia	C	Spain	100	48.4 (7.5)	100%	TAS-20	4
Melin (2010) [81]*	Chronic pain	C,M	Sweden	59	46 (NR)	88%	TAS-20	4
Melis (2014) [82]*	Pelvic pain	C,M	Italy	41	31.5 (6.4)	100%	TAS-20	5
M:lll (1002) [02]	Mixed chronic	CM	IIC A	104	42.0 (11.2)	C 40/	TAC 26	_
Millard (1992) [83]	pain	C,M	USA	194	42.8 (11.2)	64%	TAS-26	5

Mingarelli (2013) [84]	TMD	C,M	Italy	132	39.2 (13.6)	85%	TAS-20	7
Miyaoka (1996) [85]	BMS	G	Japan	50	55.8 (8.7)	100%	TAS-26	2
Montoro (2016) [86]*	Fibromyalgia	C,G,M	Spain	55	51.9 (8.8)	100%	TAS-20	6
Muftuoglu (2004) [88]	Headache	G	Turkey	50	32.1 (NR)	64%	TAS-26	4
Ozturk (2015) [94]	Mastalgia	M	Turkey	88	29.6 (8.2)	100%	TAS-20	6
Pecukonis (2009) [98]	MSK	G	USA	59	33.3 (11.9)	100%	TAS-26	6
Peñacoba (2013) [99]	Fibromyalgia	G	Spain	120	50.9 (9.8)	100%	TAS-20	5
Pepe (2014) [100]*	MSK	C,M	Italy	40	44.8 (9.7)	30%	TAS-20	6
Porcelli (2014) [101]*	IBS	C,M	Italy	177	34.5 (11.7)	71%	TAS-20	5
Portincasa (2003) [103]	IBS	G,M	Italy	100	48 (2)	27%	TAS-20	4
Saariaho (2016) [107]	Chronic pain	C,M	Finland	83	49.5 (7.19)	41%	TAS-20	5
Sayar (2004) [109] ^a	Fibromyalgia	C,M	Turkey	50	40.5 (8.8)	100%	TAS-20	4
Sayar (2004) [109] ^a	Autoimmune	C,M	Turkey	20	45.6 (14.9)	100%	TAS-20	4
Shibata (2014) [111]*	Chronic pain	C,M	Japan	439	61.1 (11)	65%	TAS-20	6
Sinikallio (2006) [113]	MSK	M	Finland	100	61.6 (11.2)	58%	TAS-20	4
Slavin-Spenny (2003)	Headache	M	USA	147	22.1 (6)	88%	TAS-20	7
[114]	Headache	IVI	USA	147	22.1 (0)	0070	1A3-20	,
Steinweg (2011) [115] ^a	Autoimmune	G,M	USA	43	59.8 (13.7)	9%	TAS-20	7
Steinweg (2011) [115] ^a	Fibromyalgia	G,M	USA	48	54.1 (13.4)	92%	TAS-20	7

Tuzer (2011) [122] ^a	Fibromyalgia	G,M	Turkey	70	39.0 (7.9)	100%	TAS-20	6
Tuzer (2011) [122] ^a	MSK	G,M	Turkey	56	44.2 (9.3)	100%	TAS-20	6
Vadacca (2014) [123] a*	Autoimmune	C,M	Italy	25	46 (11)	100%	TAS-20	5
Vadacca (2014) [123] a*	Autoimmune	C,M	Italy	24	64 (10)	100%	TAS-20	5
Valkamo (2001) [124]	Chest pain	M	Finland	200	58.1 (9.4)	34%	TAS-20	4
van Middendorp (2008) [125]	Fibromyalgia	C,G,M	Netherlands	403	46.5 (12.3)	100%	TAS-20	6
Veehof (2011) [126]	Fibromyalgia	M	Netherlands	141	43.1 (10.9)	92%	TAS-20	5
Vieira (2013)* [127]	Headache	C,M	Brazil	39	43.6 (10.7)	100%	TAS-26	6
Villani (2005) [128]	Headache	M	Italy	42	35.7 (10.6)	83%	TAS-20	3
Villani (2010) [129]	Headache	M	Italy	465	34.7 (10.9)	82%	TAS-20	3
White (2011) [132]	Chest pain	M	USA/Israel	229	50 (10.3)	56%	TAS-20	6
Wise (1994) [133] ^a	Headache	M	USA	61	37.8 (13.6)	NR	TAS-26	5
Wise (1994) [133] ^a	Headache	M	USA	39	37.8 (13.6)	NR	TAS-26	5
Yalug (2010) [134]	Headache	C,M	Turkey	300	37.4 (13.8)	83%	TAS-20	7
Yucel (2002) [135]	Headache	G	Turkey	105	33 (10)	78%	TAS-26	6
Zeng (2016) [136]	Chronic pain	С	China	147	34.9 (11.3)	100%	TAS-20	4
Zincir (2014) [139]	Chest pain	G,M	Turkey	51	33 (7.3)	73%	TAS-20	6

Youth Studies:

Cerutti (2016) [<u>18</u>] a*	Headache	C,M	Italy	53	13.4 (2.4)	57%	TAS-20	4
Gatta (2011) [<u>33</u>]	Headache	M,G	Italy	32	11.2 (2)	81%	AQC	6
Gatta (2015) [<u>34</u>] ^a	Headache	M	Italy	42	13.1 (2.4)	57%	TAS-20	5
Gatta (2015) [<u>34</u>] ^a	Headache	M	Italy	47	12.4 (2.3)	77%	TAS-20	5
Sayin (2007) [110]	Mixed chronic pain	С	Turkey	21	14.4 (2.6)	33%	TAS-26	3

Table 1. Summary of studies included in meta-analysis. *Note.* Study Design column refers to included analyses relevant for the present meta-analysis: C = correlational, G = group difference, M = mean or prevalence, a represents data from one of two samples reported in the same article. MSK = musculoskeletal pain, CPRS = complex regional pain syndrome, TMD = temporomandibular disorder, IBS = irritable bowel syndrome, BMS = burning mouth syndrome, NR = not reported. *Additional data provided by author at personal request.

	range	k	n	Mean	SD
TAS-20					
Total Score	20-100	60	5964	52.08	12.97
Difficulty Identifying Feelings	7-35	46	4654	17.79	6.75
Difficulty Describing Feelings	5-25	46	4654	13.73	5.05
Externally Oriented Thinking	8-40	45	4216	20.06	4.83
TAS-26					
Total Score	26-156	9	630	66.99	17.66

Table 2. Pooled alexithymia total and subscale scores for the overall adult sample. *Note*. Range indicates minimum to maximum score.



					Overall E	ffect and Hetero	geneity
	Alexithymia Subscale	Studies (k)	Chronic Pain (n)	Comparison (n)	Effect Size	95% CI	I ²
All Commonicans							
All Comparisons	m . 1	0.4	4056	4555	0.75	F0 60 0 0 17	0407
	Total	31	1876	1577	0.77	[0.60, 0.94]	81%
	DIF	21	1506	995	0.86	[0.63, 1.10]	85%
	DDF	21	1506	995	0.46	[0.32, 0.61]	62%
	EOT	18	1068	692	0.18	[-0.07, 0.44]	83%
Non-Clinical Compa	rison						
	Total	27	1706	1370	0.81	[0.62, 1.00]	83%
	DIF	18	1401	845	0.92	[0.66, 1.19]	86%
	DDF	18	1401	845	0.46	[0.29, 0.62]	67%
	EOT	16	963	608	0.13	[-0.15, 0.40]	85%
Medical Comparisor	1						
	Total	4	170	207	0.55	[0.34, 0.77]	0%
	DIF	3	140	150	0.51	[0.27, 0.75]	0%
	DDF	3	140	150	0.57	[0.33, 0.81]	0%

Table 3. Meta-analysis of differences in alexithymia total and subscale scores between adult samples with chronic pain and comparison samples. *Note*. Insufficient data to meta-analyze differences in EOT in chronic pain versus medical comparison.


				Overall Effect	and Heterogeneit	y	
Variable	Alexithymia subscale	Studies (k)	Participants (n)	Effect Size	95% CI	I^2	Trim and Fill (Y or N)
Pain intens	ity						
	Total	27	2749	0.20	[13, .28]	70.94	N
	Difficulty Identifying Feelings	24	2718	0.18	[.14, .23]	30.94	N
	Difficulty Describing Feelings	23	2591	0.19	[.12, .25]	57.47	N
	Externally Oriented Thinking	22	2188	0.08	[.01, .14]	51.67	N
Physical Int	terference						
	Total	19	2049	0.17	[.10, .24]	57.22	N
	Difficulty Identifying Feelings	18	1880	0.21	[.12, .30]	70.44	N
	Difficulty Describing Feelings	17	1752	0.16	[.10, .23]	46.49	N
	Externally Oriented Thinking	17	1752	0.03	[05, .11]	60.32	N
Depression							
	Total	20	2678	0.46	[.41, .51]	48.27	N
	Difficulty Identifying Feelings	21	2260	0.42	[.34, .49]	74.81	N
	Difficulty Describing Feelings	20	2132	0.38	[.31, .46]	69.36	N
	Externally Oriented Thinking	20	2132	0.20	[.12, .28]	70.43	Y
Anxiety							
	Total	22	2431	0.43	[.36, .49]	62.54	N


Difficulty Identifying Feelings	19	2114	0.46	[.40, .52]	60.71	N
Difficulty Describing Feelings	17	1933	0.38	[.31, .46]	45.10	N
Externally Oriented Thinking	18	1986	0.12	[.04, .20]	68.01	N

Table 4. Summary of meta-analyzes of correlations between alexithymia total and subscale scores with variables of interest. *Note*. Small effect size = .2; moderate effect size = .5; large effect size = .8. Significant effects are bolded. I^2 : 0-29% low heterogeneity; 30-49% moderate heterogeneity; 50-74% substantial heterogeneity; 75-100% considerable heterogeneity.

				Overall Effect a	nd Heterogeneity		
Variable	Alexithymia subscale	Studies (k)	Participants (n)	Effect Size	95% CI	I 2	Trim and Fill (Y or N)
Pain Intens	sity						
	Total	14	1621	0.09	[04, .21]	83.28	N
	Difficulty Identifying Feelings	13	1582	0.06	[03, .15]	65.23	N
	Difficulty Describing Feelings	11	1323	0.07	[40, .36]	82.27	N
	Externally Oriented Thinking	12	1522	0.06	[04, .16]	71.70	N
Physical In	nterference						
	Total	10	1101	0.06	[06, .16]	63.25	N
	Difficulty Identifying Feelings	11	1176	0.03	[05, .11]	36.42	
	Difficulty Describing Feelings	11	1176	0.04	[06, .13]	51.36	N
	Externally Oriented Thinking	11	1176	-0.01	[13, .10]	69.65	N

Table 5. Summary of meta-analyzes of partial correlations between alexithymia total and subscale scores with variables of interest, while controlling for a measure of negative affect. *Note*. Small effect size = .2; moderate effect size = .5; large effect size = .8. *I*²: 0-29% low heterogeneity; 30-49% moderate heterogeneity; 50-74% substantial heterogeneity; 75-100% considerable heterogeneity.





		c Pain G	•		arison G	•		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 Non-clinical con	trols								
Ak (2004)	54.9	11.3	30	48.5	10.3	30	3.0%	0.58 [0.07, 1.10]	
Baeza-Velas (2012)	48.69	11.45	39	39.73	12.66	22	2.9%	0.74 [0.20, 1.28]	
Castelli (2012)	47.49	10.6	45	39.87	11.1	45	3.3%	0.70 [0.27, 1.12]	
Duruk (2015)	58.97	14.36	35	48.98	9.81	47	3.2%	0.83 [0.37, 1.28]	
Fernandez (1989)	68	12.13	40	61.48	7.05	40	3.2%	0.65 [0.20, 1.10]	
Galli (2017)	48.94	13.44	80	42.19	10.23	67	3.6%	0.56 [0.22, 0.89]	
Ghiggia (2017)	52.2	13.2	181	47.2	13.3	181	3.9%	0.38 [0.17, 0.58]	+
Glaros (2005)	45.59	11.36	49	42.65	9.64	52	3.4%	0.28 [-0.11, 0.67]	+
Gregory (2000)	53.5	16.4	140	52.7	14.6	80	3.8%	0.05 [-0.22, 0.33]	+
Gregory (2005)	47.6	14.6	49	48.4	13.9	23	3.1%	-0.06 [-0.55, 0.44]	+
Gregory (2005)	58.8	13.1	46	47.6	14.6	22	3.0%	0.81 [0.29, 1.34]	
Haas (2013)	44.65	10.31	20	35.9	6.74	20	2.6%	0.98 [0.32, 1.64]	
Huang (2016)	50	10.44	20	31	7	10	1.9%	1.95 [1.03, 2.88]	
Karahan (2016)	53.58	9.7	148	39.67	10.09	100	3.8%	1.41 [1.12, 1.69]	-
Marino (2015)	70.6	13.2	58	48.3	7.8	58	3.2%	2.04 [1.59, 2.50]	
Miyaoka (1996)	75.7	7.2	50	70.2	8	24	3.1%	0.73 [0.23, 1.23]	—
Montoro (2016)	57.44	10.94	55	42.18	7.21	34	3.1%	1.56 [1.07, 2.05]	
Muftuoglu (2004)	12.2	3.2	50	9.4	0.5	50	3.3%	1.21 [0.79, 1.64]	
Pecukonis (2009)	77.2	15.8	59	67.1	13.1	53	3.5%	0.69 [0.31, 1.07]	-
Penacoba (2013)	58.33	10.39	120	49.44	12.44	120	3.8%	0.77 [0.51, 1.04]	
Sayer (2004)	55.6	11.6	50	48.6	7.8	21	3.0%	0.65 [0.13, 1.17]	
Sayer (2004)	50.6	7.1	20	48.6	7.8	21	2.7%	0.26 [-0.35, 0.88]	
Steingweg (2011)	53.42	2.08	43	51.51	2.38	18	2.8%	0.87 [0.30, 1.44]	
Steingweg (2011)	56.57	1.91	48	51.51	2.38	18	2.5%	2.44 [1.75, 3.14]	
Tuzer (2011)	60.43	13.17	70	53.06	12.98	72	3.6%	0.56 [0.23, 0.90]	
Tuzer (2011) Tuzer (2011)	59.39	11.06	56	53.06	12.98	72	3.5%	0.52 [0.16, 0.87]	
Yucel (2002)	11	4.2	105	8.22	3.69	70	3.7%	0.69 [0.38, 1.00]	
Subtotal (95% CI)	- 11	4.2	1706	0.22	3.03	1370	86.7%	0.81 [0.62, 1.00]	
Heterogeneity: Tau² = 1	0.21: Chi	2 - 157 A		8 /D ~ N I	000013-1			0.01 [0.02, 1.00]	•
Test for overall effect: 2				0 (1 ~ 0.1	00001), 1	- 03 70			
1 6 5 1 101 O 7 6 1 a 11 6 11 6 C L . 2	L - 0.23 (- 0.000	301)						
1.1.2 Clinical controls	;					47	•		
Duruk (2015)	58.97	14.36	35	51.51	11.9	66	3.3%	0.58 [0.16, 1.00]	
Jerjes (2007)	54.1	12.8	51	45.5	12	51	3.4%	0.69 [0.29, 1.09]	
Kugu (2009)	56.53	11.76	54	49.75	8.68	33	3.3%	0.63 [0.18, 1.07]	
Lumley (1997)	67.4	8.2	30	64.31	11.59	57	3.3%	0.29 [-0.15, 0.73]	↓
Subtotal (95% CI)	2		170			207	13.3%	0.55 [0.34, 0.77]	•
Heterogeneity: Tau² = 1	0.00: Chi	²= 1.91	df = 3 (P.	= 0.59\	$ ^2 = 0\%$				
Test for overall effect: 2				0.00/,	. 0.0				
. 551.01 0101411 011001. 2	(- 17						
Total (95% CI)			1876			1577	100.0%	0.77 [0.60, 0.94]	•
Heterogeneity: Tau ² =	0.18; Chi	² = 161.2	5, df = 3i	0 (P < 0.1	00001): I	²= 81%			
Test for overall effect: 2			•	*-	//				-4 -2 0 2
Test for subgroup diffe				/P = 0.0	18) P = 6	7.5%			Comparison Sample Chronic Pain Sam